MiMedx Group, Inc Stock Prediction
AI-powered sentiment analysis and prediction trends for MDXG, updated each market day.
MDXG AI Sentiment
AI sees no strong directional signal for MiMedx Group, Inc stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About MiMedx Group, Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Sector
Exchange
Market Cap
$598,723,341
Cap Tier
Employees
808
Headquarters
MARIETTA, GA
Listed Since
Aug. 22, 2007
Website
MDXG Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
MDXG Volatility
MiMedx Group, Inc has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
